Compact by design
Typically 30–50 amino acids long, our peptides combine antibody-like recognition with compact, synthetically accessible structures.
OUR TECHNOLOGY
We build target specificity into peptide discovery, combining molecular biology, artificial intelligence, and high-performance computing.
RECOGNITION AT THE MOLECULAR LEVEL
THE DESIGNED BIOLOGICS ADVANTAGE
The right interaction matters.
So do the interactions you avoid.
Our platform integrates computational negative selection and off-target screening into the design process. The aim is to distinguish intended targets from related proteins while minimizing unwanted interactions.
Published research includes a peptide that recognized a disease-associated receptor variant without detectable binding to its normal counterpart under the tested conditions.
See the experimental evidenceCOMPACT MOLECULES. EXPANSIVE POTENTIAL.
Typically 30–50 amino acids long, our peptides combine antibody-like recognition with compact, synthetically accessible structures.
Artificial intelligence, genetic algorithms, molecular dynamics, and high-performance computing help explore sequence possibilities and prioritize candidates.
Engineer inhibitors, binding agents, diagnostic reagents, or research tools. Target different regions of a protein or explore multifunctional constructs.
A repeatable discovery platform supports proprietary programs and partner-led projects, from target exploration to experimental validation.
OUR APPROACH
Computation guides discovery.
Experiments establish what works.
Define the biological interaction, desired function, and selectivity requirements.
Explore peptide sequences and assess predicted target binding and off-target interactions.
Test promising candidates experimentally and use the findings to guide optimization.
THE NEXT DISCOVERY STARTS WITH A CONVERSATION
Explore what precision peptide design could make possible for your project.